The CDKN2A (p16) gene and human cancer.

PubWeight™: 1.46‹?› | Rank: Top 5%

🔗 View Article (PMC 2230107)

Published in Mol Med on January 01, 1997

Authors

W D Foulkes1, T Y Flanders, P M Pollock, N K Hayward

Author Affiliations

1: Department of Medicine, McGill University, Montreal General Hospital, Canada.

Articles citing this

Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev (1998) 5.14

DNA copy number losses in human neoplasms. Am J Pathol (1999) 2.73

T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol (2004) 2.11

RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res (2014) 1.34

Cell cycle control, checkpoint mechanisms, and genotoxic stress. Environ Health Perspect (1999) 1.22

Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer (2010) 1.18

Effect of HCV infection on expression of several cancer-associated gene products in HCC. World J Gastroenterol (1999) 1.15

CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A. Am J Pathol (2001) 1.12

Alteration of p16 and p15 genes in human uterine tumours. Br J Cancer (1999) 0.99

Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. The Melanoma Cooperative Group. Br J Cancer (2000) 0.91

p16 mutation spectrum in the premalignant condition Barrett's esophagus. PLoS One (2008) 0.87

Genetics of coronary artery disease: focus on genome-wide association studies. Am J Transl Res (2009) 0.83

Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li-Fraumeni syndrome. Br J Cancer (1999) 0.81

Pancreatic Cancer Genetics. Int J Biol Sci (2016) 0.81

Distinguishing Lung Adenocarcinoma from Lung Squamous Cell Carcinoma by Two Hypomethylated and Three Hypermethylated Genes: A Meta-Analysis. PLoS One (2016) 0.81

An Old Story Retold: Loss of G1 Control Defines A Distinct Genomic Subtype of Esophageal Squamous Cell Carcinoma. Genomics Proteomics Bioinformatics (2015) 0.80

Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth. PLoS One (2014) 0.80

Abundant copy-number loss of CYCLOPS and STOP genes in gastric adenocarcinoma. Gastric Cancer (2015) 0.75

Differential Expression of ADAM23, CDKN2A (P16), MMP14 and VIM Associated with Giant Cell Tumor of Bone. J Cancer (2015) 0.75

The association between methylated CDKN2A and cervical carcinogenesis, and its diagnostic value in cervical cancer: a meta-analysis. Ther Clin Risk Manag (2016) 0.75

Age-dependent development of liver fibrosis in Glmp (gt/gt) mice. Fibrogenesis Tissue Repair (2016) 0.75

Articles cited by this

A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00

5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10

Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32

Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42

A cancer family syndrome in twenty-four kindreds. Cancer Res (1988) 6.39

Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (1994) 6.06

Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res (1994) 5.64

Germline p16 mutations in familial melanoma. Nat Genet (1994) 5.59

Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet (1995) 4.86

Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63

CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res (1996) 4.42

Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res (1995) 4.28

Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med (1995) 4.10

Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet (1996) 4.09

Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet (1995) 3.76

High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res (1996) 3.18

Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet (1994) 3.05

Deletion of p16 and p15 genes in brain tumors. Cancer Res (1994) 3.03

Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science (1992) 2.89

Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci U S A (1994) 2.64

Mad-related genes in the human. Nat Genet (1996) 2.51

p16 gene in uncultured tumours. Nature (1994) 2.47

Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA (1995) 2.43

Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med (1995) 2.34

Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science (1994) 2.16

Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet (1995) 2.11

Mutations associated with familial melanoma impair p16INK4 function. Nat Genet (1995) 1.69

Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58

Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res (1995) 1.50

Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res (1994) 1.29

Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer (1996) 1.25

Tumour spectrum in the FAMMM syndrome. Br J Cancer (1981) 1.24

Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res (1995) 1.22

Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet (1995) 1.18

Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res (1994) 1.15

Systemic cancer and the FAMMM syndrome. Br J Cancer (1990) 1.12

Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene (1995) 1.11

MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet (1994) 1.09

Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res (1995) 1.07

Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood (1996) 1.06

Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology (1996) 1.05

Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res (1996) 1.04

Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer. Int J Cancer (1995) 1.04

Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Br J Cancer (1996) 1.02

Alterations of the p15, p16,and p18 genes in osteosarcoma. Cancer Genet Cytogenet (1996) 1.01

Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene (1995) 1.01

Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet (1993) 0.97

Are malignant melanoma patients at higher risk for a second cancer? Cancer (1991) 0.97

Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. Br J Cancer (1995) 0.96

Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood (1995) 0.96

Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int J Cancer (1996) 0.94

Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res (1996) 0.93

Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers. Int J Cancer (1996) 0.93

LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int J Cancer (1995) 0.92

Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes Chromosomes Cancer (1995) 0.92

Hereditary melanoma and the dysplastic nevus syndrome: the risk of cancers other than melanoma. J Am Acad Dermatol (1987) 0.91

Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res (1995) 0.90

Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. J Urol (1995) 0.90

Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors. Oncogene (1996) 0.89

Mutations of the p16 gene in gliomas. Oncogene (1996) 0.89

Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. J Natl Cancer Inst (1996) 0.89

High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. J Natl Cancer Inst (1995) 0.89

Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. J Natl Cancer Inst (1996) 0.87

Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas. Blood (1995) 0.87

Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene (1995) 0.87

Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas. Int J Cancer (1996) 0.86

Linkage analysis in Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome families. Effect of naevus count. Melanoma Res (1993) 0.86

Alterations of CDKN2 (p16) in non-small cell lung cancer. Genes Chromosomes Cancer (1995) 0.85

Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet (1994) 0.84

Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene (1995) 0.84

Loss of heterozygosity on chromosome 9 in human breast cancer: association with clinical variables and genetic changes at other chromosome regions. Int J Cancer (1995) 0.83

Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis. Oncogene (1995) 0.83

Loss of heterozygosity at 9p21 loci and mutations of the MTS1 and MTS2 genes in human lung cancers. Int J Cancer (1995) 0.81

Infrequent somatic alteration of p16/MTS1 in human primary superficial bladder cancers. Cancer Lett (1996) 0.81

Homozygous deletions of p16INK4A/MTS1 and p15INK4B/MTS2 genes in glioma cells and primary glioma tissues. Cancer Lett (1995) 0.79

Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma. Br J Cancer (1996) 0.79

Familial melanoma and pancreatic cancer. Ligurian Skin Tumor Study Group. N Engl J Med (1996) 0.79

p15ink4B and p16ink4 gene inactivation in acute lymphocytic leukemia. Blood (1995) 0.78

Infrequent CDKN2 mutation in human differentiated thyroid cancers. Mol Carcinog (1996) 0.78

Status and expression of the p16INK4 gene in human thyroid tumors and thyroid-tumor cell lines. Int J Cancer (1996) 0.77

Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias. Br J Haematol (1995) 0.76

Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T lineage. Leukemia (1996) 0.76

Articles by these authors

Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet (2000) 4.74

A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs. Am J Hum Genet (1999) 2.15

Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer (2005) 2.13

Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J Cell Sci (1996) 1.99

A Taq I polymorphism for the human transforming growth factor alpha gene (TGFA). Nucleic Acids Res (1987) 1.88

Genome scan of schizophrenia. Am J Psychiatry (1998) 1.74

Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res (2000) 1.72

MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet (2001) 1.67

Leptin and the risk of Barrett's oesophagus. Gut (2008) 1.54

Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement. Eur Respir J (2007) 1.43

Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol (1996) 1.36

Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res (1997) 1.33

The contribution of the DFNB1 locus to neurosensory deafness in a Caucasian population. Am J Hum Genet (1995) 1.30

Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer (1996) 1.25

Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res (1994) 1.24

Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet (1995) 1.18

Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res (1996) 1.10

Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res (1995) 1.10

CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res (1997) 1.07

Separate and interacting effects within the catechol-O-methyltransferase (COMT) are associated with schizophrenia. Mol Psychiatry (2005) 1.04

Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst (2010) 1.04

Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Res (2001) 1.03

Analysis of gene amplification in head-and-neck squamous-cell carcinoma. Int J Cancer (1991) 1.00

Second stage of a genome scan of schizophrenia: study of five positive regions in an expanded sample. Am J Med Genet (2000) 0.98

Germline CDKN2A mutations in childhood melanoma. J Natl Cancer Inst (1997) 0.98

Localization of multiple melanoma tumor-suppressor genes on chromosome 11 by use of homozygosity mapping-of-deletions analysis. Am J Hum Genet (2000) 0.97

Functional reassessment of P16 variants using a transfection-based assay. Int J Cancer (1999) 0.97

Hepatocellular carcinoma mutation. Nature (1991) 0.95

Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene (1997) 0.94

A genetic model of melanoma tumorigenesis based on allelic losses. Genes Chromosomes Cancer (1995) 0.93

Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mutat (1998) 0.90

Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and MYCL1 regions of chromosome arm 1p in 7 Australian pedigrees. Genomics (1992) 0.90

Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. Oncogene (1995) 0.89

Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res (2002) 0.88

The phospholipase C beta 3 gene located in the MEN1 region shows loss of expression in endocrine tumours. Hum Mol Genet (1994) 0.88

PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Res (2002) 0.87

p53 gene in hepatocellular carcinomas from Australia. Cancer Detect Prev (1994) 0.86

CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin. Int J Cancer (2001) 0.86

Clonal loss of INT-2 alleles in sporadic and familial pancreatic endocrine tumours. Br J Cancer (1990) 0.86

Multiple splicing variants of cdc25B regulate G2/M progression. Biochem Biophys Res Commun (1999) 0.86

Simple tandem repeat allelic deletions confirm the preferential loss of distal chromosome 6q in melanoma. Int J Cancer (1994) 0.86

Loss of somatic heterozygosity in hepatocellular carcinoma. Cancer Res (1991) 0.86

CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. Int J Cancer (1997) 0.85

Linkage mapping of melanoma (MLM) using 172 microsatellite markers. Genomics (1992) 0.85

Evidence for microsatellite instability in bilateral breast carcinomas. Cancer Lett (2000) 0.85

Single base mutation in the hormone binding domain of the thyroid hormone receptor beta gene in generalised thyroid hormone resistance demonstrated by single stranded conformation polymorphism analysis. Biochem Biophys Res Commun (1991) 0.83

Involvement of p16CDKN2A in cell cycle delays after low dose UV irradiation. Mutat Res (1998) 0.83

Lack of augmentation of tumor spectrum or severity in dual heterozygous Men1 and Rb1 knockout mice. Oncogene (2006) 0.83

Molecular tools for presymptomatic testing in multiple endocrine neoplasia type 1. J Intern Med (1995) 0.82

Origin of rare Ha-ras alleles: relationship of VTR length to a 5' polymorphic Xho I site. Genet Res (1989) 0.81

Loss of alleles on the short arm of chromosome 11 in a hepatoblastoma from a child with Beckwith-Wiedemann syndrome. Hum Genet (1988) 0.81

Loss of heterozygosity studies in squamous cell carcinomas of the head and neck. Head Neck (1997) 0.80

Restoration of CDKN2A into melanoma cells induces morphologic changes and reduction in growth rate but not anchorage-independent growth reversal. J Invest Dermatol (1997) 0.80

Ocular melanoma is not associated with CDKN2A or MC1R variants--a population-based study. Melanoma Res (2003) 0.79

Mutation analysis of the CDKN2A promoter in Australian melanoma families. Genes Chromosomes Cancer (2001) 0.79

Linkage analysis in familial melanoma kindreds to markers on chromosome 6p. Int J Cancer (1994) 0.79

A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome. QJM (1995) 0.78

Effect of N-hydroxyparacetamol on cell cycle progression. Biochem Pharmacol (1986) 0.78

Prophylactic but not therapeutic activity of a monoclonal antibody that neutralizes the binding of VEGF-B to VEGFR-1 in a murine collagen-induced arthritis model. Rheumatology (Oxford) (2008) 0.78

Cutaneous malignant melanoma in women is uncommonly associated with a family history of melanoma in first-degree relatives: a case-control study. Melanoma Res (1996) 0.78

UV induction of transforming growth factor alpha in melanoma cell lines is a posttranslational event. J Cell Physiol (1992) 0.77

Refined localization of the melanoma (MLM) gene on chromosome 9p by analysis of allelic deletions. Oncogene (1994) 0.77

The MLLT3 gene maps between D9S156 and D9S171 and contains an unstable polymorphic trinucleotide repeat. Genomics (1994) 0.76

Genomic organization and complete cDNA sequence of the human phosphoinositide-specific phospholipase C beta 3 gene (PLCB3). Genomics (1995) 0.76

Lack of genetic and epigenetic changes in CDKN2A in melanocytic nevi. J Invest Dermatol (2001) 0.76

Loss of allelic heterozygosity on distal chromosome 1p in Merkel cell carcinoma. A marker of neural crest origins? Cancer Genet Cytogenet (1991) 0.76

Conditions for generating well-resolved human DNA fingerprints using M13 phage DNA. Nucleic Acids Res (1990) 0.75

Confirmation of susceptibility locus on chromosome 13 in Australian breast cancer families. Hum Genet (1996) 0.75

Genetic studies of thymic carcinoids in multiple endocrine neoplasia type 1. J Med Genet (1994) 0.75

Rare c-Ha-ras-1 alleles in human leukaemia. Nucleic Acids Res (1989) 0.75

Effect of N-hydroxyparacetamol on DNA, RNA, and protein synthesis and chromatin structure. Mol Pharmacol (1986) 0.75

p-Aminophenol induced DNA damage and cytotoxicity enhanced by autoxidation. Life Sci (1985) 0.75

No support for linkage to the bipolar regions on chromosomes 4p, 18p, or 18q in 43 schizophrenia pedigrees. Am J Med Genet (2000) 0.75

Haplotype analysis limits the position of the familial melanoma locus on 9p to the D9S169-D9S156 interval. Melanoma Res (1994) 0.75

Predictive diagnosis of multiple endocrine neoplasia (MEN 1) in four Australian kindreds. Aust N Z J Med (1996) 0.75

Inhibition of DNA, RNA and protein synthesis and chromatin alteration by N-hydroxyphenacetin. Xenobiotica (1987) 0.75

The impact of the Human Genome Project on medical genetics. Trends Mol Med (2001) 0.75

Inhibition of DNA synthesis and alteration to DNA structure by the phenacetin analog p-aminophenol. Biochem Pharmacol (1982) 0.75

A homologue of the Drosophila Son of sevenless gene maps to mouse chromosome 17. Genomics (1993) 0.75

Genetic mapping of the multiple endocrine neoplasia type 1 locus at 11q13. J Intern Med (1995) 0.75

Microsatellite instability in melanoma. Melanoma Res (1994) 0.75

G protein mutations in tumours of the pituitary, parathyroid and endocrine pancreas. Biochem Biophys Res Commun (1995) 0.75

Spontaneous and 4-nitroquinoline 1-oxide-induced G2 chromosome aberrations in lymphoblasts from familial melanoma patients. Cancer Genet Cytogenet (1989) 0.75